Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.61 |
| ▸ | PLAT | P00750 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488811 | 0.80 | MAPT (0.46) | PLAUPLATMAPTKDM4EMEN1 | |
| SCHEMBL18952096 | 0.80 | MAP4K3 (0.47) | PLAUPLATMAPTKDM4EMEN1 | |
| SCHEMBL3291997 | 0.76 | ALDH1A1 (0.42) | PLAUPLATMAPTKDM4EMEN1 | |
| SCHEMBL15907689 | 0.76 | MAPT (0.42) | PLAUPLATMAPTKDM4EMEN1 | |
| SCHEMBL16598517 | 0.76 | ADK (0.47) | PLAUPLATMAPTADKAPP | |
| SCHEMBL2034977 | 0.75 | CSF1R (0.40) | PLAUPLATCYP1A2CYP3A4HPGD | |
| SCHEMBL24853347 | 0.75 | MAPT (0.47) | PLAUPLATMAPTKDM4EMEN1 | |
| SCHEMBL31396376 | 0.75 | MAPT (0.47) | PLAUPLATMAPTKDM4EMEN1 | |
| SCHEMBL16424392 | 0.74 | GRM5 (0.42) | PLAUPLATMEN1CYP2C9KMT2A | |
| SCHEMBL1772484 | 0.74 | CASP3 (0.51) | MAPTKDM4EMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| EP-1044967-B1 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6673789-B2 | TREATING INFILTRATION OF IMMUNE CELLS INTO INFLAMMATORY SITES | PFIZER, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | DICKINSON ROGER PETER (GB) | 2003-10-30 | — | — | US | disclosed |
| US-6583162-B1 | 2-pyridinylguanidine urokinase inhibitors | WARNER-LAMBERT COMPANY | 2003-06-24 | — | — | US | disclosed |
| EP-1044967-A2 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER INC. (US) | 2000-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885PLAT 48/4885MAPT 2392/4885 |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | PLAU, SERPINE1, REN | PLAU 1/4885PLAT 9/4885MAPT 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.